Literature DB >> 35153144

Endocrine abnormality in paraneoplastic syndrome.

Michael C Onyema1, Eftychia E Drakou2, Georgios K Dimitriadis3.   

Abstract

Paraneoplastic syndromes denote rare but notable phenomena caused by the tumour mediated release of bioactive substances. Peptide and non-peptide hormone causes are explored with a particular focus on pathogenesis, symptoms, diagnosis and treatment. Early detection and management of paraneoplastic syndromes can improve morbidly and mortality; definitive treatment remains effective surgical or anti-tumour therapies. Pituitary autoimmunity may provide a novel presentation of paraneoplastic syndromes for which further research is warranted.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  cytokines; endocrine; hormones; paraneoplastic syndrome; peptides; pituitary autoimmunity

Mesh:

Year:  2022        PMID: 35153144     DOI: 10.1016/j.beem.2022.101621

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  1 in total

1.  [Diagnostics and treatment of clinically relevant paraneoplastic syndromes].

Authors:  Katharina Schütte; Karolin Trautmann-Grill
Journal:  Schmerz       Date:  2022-10-19       Impact factor: 1.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.